A novel lateral flow immunoassay for the rapid detection of anti-Dsg3 IgG serum autoantibodies in pemphigus vulgaris
- 1 March 2018
- journal article
- research article
- Published by Wiley in Experimental Dermatology
- Vol. 27 (3), 233-237
- https://doi.org/10.1111/exd.13488
Abstract
Pemphigus vulgaris (PV) is a severe autoimmune blistering disease of the skin and mucous membranes. As autoantibodies play an essential role in the disease pathogenesis, the serological detection of anti-desmoglein 3 IgG represents a central tool in the diagnosis of the disease. In this study, we show the validation of a novel lateral flow immunoassay (LFIA) which rapidly detects anti-desmoglein 3 (Dsg3) IgG in human serum. In contrast to other diagnostic procedures, the assay is compact and simple to perform and delivers a fast "yes" or "no" answer within 10 minutes without additional hardware requirements for test evaluation. For validation, a blinded collection of 200 sera including 100 sera from 14 PV patients, 75 sera from 24 bullous pemphigoid patients and 25 sera from 6 patients with pemphigus foliaceus collected at different time points during disease was used. Presence or non-presence of anti-Dsg3 IgG within sera was confirmed using a commercially available Dsg3-ELISA. For qualitative evaluation, Dsg3-LFIA test results were assessed by two independent groups of human observers. Furthermore, quantitative evaluation using POCScan reader was applied. The Dsg3-LFIA demonstrated reliable test results with a sensitivity and specificity of 78.1% and 97.1%, respectively. Test results from POCScan and human observers showed a substantial agreement. The Dsg3-LFIA represents a new diagnostic tool for the immediate and reliable detection of anti-desmoglein 3 serum IgG autoantibodies that does not require additional hardware. Further prospective trials are warranted to validate the Dsg3 LFIA in pemphigus.Keywords
Funding Information
- LOEWE Zentrum AdRIA (245/10-21)
- Deutsche Forschungsgemeinschaft (FOR 2497)
This publication has 24 references indexed in Scilit:
- Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patientsExperimental Dermatology, 2010
- Serum and salivary desmoglein 1 and 3 enzyme‐linked immunosorbent assay in pemphigus vulgaris: correlation with phenotype and severityJournal of the European Academy of Dermatology and Venereology, 2010
- Desmoglein 1 and 3 enzyme‐linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activityJournal of the European Academy of Dermatology and Venereology, 2007
- IgG reactivity against non‐conformational NH2‐terminal epitopes of the desmoglein 3 ectodomain relates to clinical activity and phenotype of pemphigus vulgarisExperimental Dermatology, 2006
- Evaluation of desmoglein enzyme‐linked immunosorbent assay (ELISA) in Indian patients with pemphigus vulgarisInternational Journal of Dermatology, 2006
- The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levelsBritish Journal of Dermatology, 2001
- Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigusBritish Journal of Dermatology, 1999
- Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesionCell, 1991
- Pemphigus and pemphigoid: A review of the advances made since 1964Journal of the American Academy of Dermatology, 1979